Margaret Ashton-Key

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Klebsiella Pneumoniae

Diffuse Large B Cell Lymphoma

Epidermal Growth Factor Receptor

Top Venues

Exploration of targeted anti-tumor therapy

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Amatta Mirandari, Helen Parker, Margaret Ashton-Key, Benjamin Stevens, Renata Walewska, Kostas Stamatopoulos, Dean J Bryant, David G Oscier, Jane Gibson, Jonathan C Strefford
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Findlay Bewicke-Copley, Koorosh Korfi, Shamza Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon L Barrans, Suzan Jl van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon A Rule, Nicola Crosbie, Andrew James Clear, Maria Calaminici, Hendrik Friedrich Peter Runge, Robert K Hills, David W Scott, Lisa M Rimsza, Geetha Menon, Chulin Sha, John Davies, Ai Nagano, Andrew John Davies, Daniel Painter, Alexandra G Smith, John G Gribben, Kikkeri N Naresh, David Robert Westhead, Jessica Okosun, Andrew J Steele, Daniel James Hodson, Sriram Balasubramanian, Peter W M Johnson, Jun Wang, Jude Fitzgibbon
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma. Blood advances (2022)
Malgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, Chantal E Hargreaves, Chern Lee, Russell Foxall, Matthew J Carter, Stephen A Beers, Kathleen N Potter, Christopher R Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew J J Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W Scott, Laurie H Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trněný, Christopher K Rushton, Graham W Slack, Pedro Farinha, Jonathan C Strefford, Mikkel Z Oestergaard, Ryan D Morin, Mark S Cragg
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood advances 5 (15) (2021)
Ali Roghanian, Guangan Hu, Christopher Fraser, Maneesh Singh, Russell B Foxall, Matthew J Meyer, Emma Lees, Heather Huet, Martin J Glennie, Stephen A Beers, Sean H Lim, Margaret Ashton-Key, Stephen M Thirdborough, Mark S Cragg, Jianzhu Chen
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression. Cancer immunology research 7 (11) (2019)